Free Trial

Cronos Group (CRON) Competitors

Cronos Group logo
$2.08 +0.04 (+1.96%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$2.07 -0.01 (-0.48%)
As of 08:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRON vs. ACB, CGC, OGI, SNDL, TLRY, MOR, KYMR, ALVO, IMVT, and CRNX

Should you be buying Cronos Group stock or one of its competitors? The main competitors of Cronos Group include Aurora Cannabis (ACB), Canopy Growth (CGC), Organigram Global (OGI), SNDL (SNDL), Tilray Brands (TLRY), MorphoSys (MOR), Kymera Therapeutics (KYMR), Alvotech (ALVO), Immunovant (IMVT), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "medical" sector.

Cronos Group vs. Its Competitors

Aurora Cannabis (NASDAQ:ACB) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Cronos Group has lower revenue, but higher earnings than Aurora Cannabis. Cronos Group is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$246.72M1.04$1.63M$0.1141.45
Cronos Group$117.61M6.82$41.08M$0.1316.00

47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by insiders. Comparatively, 6.9% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
3.67
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Cronos Group has a net margin of 39.69% compared to Aurora Cannabis' net margin of 1.32%. Aurora Cannabis' return on equity of 0.13% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis1.32% 0.13% 0.10%
Cronos Group 39.69%-0.07%-0.07%

In the previous week, Aurora Cannabis had 1 more articles in the media than Cronos Group. MarketBeat recorded 3 mentions for Aurora Cannabis and 2 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.57 beat Aurora Cannabis' score of 0.00 indicating that Cronos Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cronos Group
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Aurora Cannabis has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.

Summary

Aurora Cannabis beats Cronos Group on 10 of the 16 factors compared between the two stocks.

Get Cronos Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRON vs. The Competition

MetricCronos GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$786.79M$2.68B$5.50B$8.95B
Dividend YieldN/A1.79%5.25%4.04%
P/E Ratio16.008.9826.9720.11
Price / Sales6.82714.59425.92119.81
Price / Cash4,384.08159.8036.8257.86
Price / Book0.724.517.985.56
Net Income$41.08M$31.26M$3.16B$248.40M
7 Day Performance4.00%3.57%2.36%4.67%
1 Month Performance6.12%1.28%2.15%6.64%
1 Year Performance-7.14%1.08%33.78%21.31%

Cronos Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRON
Cronos Group
2.0494 of 5 stars
$2.08
+2.0%
N/A-7.6%$786.79M$117.61M16.00450News Coverage
ACB
Aurora Cannabis
0.0983 of 5 stars
$4.24
+2.2%
N/A-7.9%$238.33M$246.72M38.551,130
CGC
Canopy Growth
0.6793 of 5 stars
$1.22
flat
$2.00
+63.9%
-80.4%$224.32M$225.65M-0.303,150News Coverage
OGI
Organigram Global
0.9599 of 5 stars
$1.35
flat
N/A-8.9%$180.82M$117.47M13.50860News Coverage
Gap Down
SNDL
SNDL
3.513 of 5 stars
$1.21
-1.6%
$3.63
+199.6%
-29.9%$317.96M$671.81M-4.172,516
TLRY
Tilray Brands
2.1373 of 5 stars
$0.41
+3.4%
$1.92
+362.5%
-66.2%$417.09M$210.48M-0.392,650
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
KYMR
Kymera Therapeutics
3.1715 of 5 stars
$43.64
-1.1%
$59.61
+36.6%
+35.9%$2.84B$47.07M-14.08170
ALVO
Alvotech
3.9995 of 5 stars
$9.12
-0.2%
$18.00
+97.4%
-27.5%$2.75B$491.98M24.651,032
IMVT
Immunovant
1.3922 of 5 stars
$16.00
-0.6%
$38.33
+139.6%
-38.9%$2.73BN/A-5.84120
CRNX
Crinetics Pharmaceuticals
3.1512 of 5 stars
$28.76
-4.0%
$74.56
+159.2%
-35.3%$2.69B$1.04M-7.53210

Related Companies and Tools


This page (NASDAQ:CRON) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners